Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Psynova announces patent deal with Cambridge University

Specialists in novel biomarkers for Neuropsychiatric illnesses, Psynova, have obtained an option to licence a patent owned by Cambridge University Technical Services (CUTS), which protects an invention made by Psynova co-founder Dr Sabine Bahn. The invention relates to a method for monitoring and diagnosing psychotic disorders, including Schizophrenia.

CUTS is Cambridge University's wholly-owned trading company and the legal entity through which Cambridge University conducts its technology licencing deals and other forms of commercial activity. Cambridge Enterprise, the University office that encourages and supports the commercialisation of knowledge from all parts of the University, also helped negotiate the option agreement together with Psynova.

“Psynova is pleased to take an option over Dr Bahn's invention which complements the patent portfolio that Psynova licenced from CUTS on an exclusive worldwide basis earlier this year. This new deal emphasises the commercial value of Dr Bahn's research and builds on the excellent working relationship between Psynova and Cambridge University.”, commented Paul Rodgers, Chairman of Psynova.

For further information on Psynova Ltd. and all other media enquiries, please contact:
Paul Rodgers
Psynova Ltd
Telephone/Fax: +44 (0) 1223 703146
Mobile: +44 (0) 7802 157393

Psynova Ltd. is a new company, established in 2005 by Dr Sabine Bahn MD, Ph.D, MRCPsych, and Prof Chris Lowe PhD of the University of Cambridge, for the commercial development and exploitation of novel biomarkers for Neuropsychiatric illnesses.

Building on 12 years of ground-breaking research by Dr Bahn, Psynova has close links with Bahn's laboratory within the newly established Centre for Neuropsychiatric Research (CCNR) at the University of Cambridge. Initially concentrating on Schizophrenia and Bipolar Affective Disorder (previously referred to as manic depression) Psynova intends to longer term, move into related therapeutic areas, such as depression, neurodegenerative disorders and substance abuse, as well as sleep and eating disorders, where it has extensive relevant expertise.

At present there are no validated biomarkers and diagnostics for these disorders, nor are the underlying disease processes understood, meaning symptomatic relief only, from current medications on offer. Psynova intends to address all of these deficiencies.

Cambridge Enterprise facilitates the commercial development of the University of Cambridge’s intellectual property. Achieved through licence agreements, Cambridge Enterprise Seed Funds invests in new companies; provide business creation support and a complete service for staff undertaking consultancy work with external organizations. Cambridge Enterprise licences patents and other intellectual property to existing companies, both large and small, as well as to spinouts formed to exploit University technology. Working together with venture capital funds and private investors, Cambridge Enterprise generates companies with strong commercial potential.

During 2004-5, Cambridge University applied for 43 patents based on 127 invention disclosures, while a total of 41 new licences and other commercial agreements were completed. Income from patent and software licences exceeded £2.5 million, and demand for academics' technical advice added a further £1.5 million of revenue. Three new University spin-out companies were launched. Smart Holograms is one of the Cambridge Enterprise Seed Funds earlier investments. Further information on Cambridge Enterprise can be found at

Publisher Contact Information:

Psynova Ltd
+44 (0) 1223 703146

Company profile of Psynova Ltd
Past press releases of Psynova Ltd .


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jan 10€20.0MBusiness applications
Jan 10€20.0MBiotechnology
Jan 10€13.5MArtificial Intelligence
Jan 9€4.0MSoftware development
Jan 9N/AInternet services
Jan 9€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.